Technology | Ultrasound Women's Health | December 03, 2018

GE Healthcare Introduces Invenia ABUS 2.0

Updated automated breast ultrasound system features improved data acquisition, patient comfort enhancements

GE Healthcare Introduces Invenia ABUS 2.0

December 3, 2018 — GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This device is the only U.S. Food and Drug Administration (FDA)-approved ultrasound supplemental breast screening technology, according to GE, specifically designed for detecting cancer in dense breast tissue. When used in addition to mammography, Invenia ABUS can improve breast cancer detection by 55 percent over mammography[1] alone.[2]

“We are committed to informing patients about breast density, and offering supplemental screening options,” said Sophia Roumanis, M.D., section head of breast imaging and intervention, Beaumont Breast Care Center, Dearborn, Mich. “We are thrilled to add this advanced ultrasound technology to our breast cancer screening program, which allows better visibility of dense breast tissue during breast cancer screenings.”

More than 40 percent of women in the U.S. have dense breast tissue[3], which is one of the strongest common risk factors for developing breast cancer. Breast density is a measurement of the amount of fatty tissue versus the amount of fibrous tissue in the breast. Both cancer and dense tissue appear white on a mammogram, so looking for tumors in women with dense breasts can be like looking for a snowball in a snowstorm. Because of this, tumors are often unseen – or “masked” – on mammography exams.

“Our goal is to find cancers as early as possible to offer the best potential outcome for the patient,” commented Vidya Pai, M.D., section head of breast imaging and intervention, Beaumont Hospital, Royal Oak, Mich. “By offering this supplemental screening to mammography for patients with dense breast tissue, we anticipate improving detection for small cancers that may not be seen on a mammogram alone in these women.”

Launched in 2014, Invenia ABUS has been installed at hundreds of facilities around the world. The new Invenia ABUS 2.0 builds on its predecessor to enhance the exam experience for both operators and patients, including new features that further customize the exam based on the patient’s body:

  • Efficient exams: The cSound Imageformer, a software-based graphics processor, provides a reproducible and operator-independent acquisition method to achieve consistent, high-quality results. cSound imaging allows significantly more data to be collected and used to create every image. Traditional hand-held ultrasound parameters such as focal zones and gain are automatically optimized. No image manipulation is required, so that high image quality is consistent from operator to operator with the touch of a button; and
  • Improving the patient experience: The gentle shape of the Reverse Curve transducer follows the natural contour of the breast, providing patient comfort, thorough contact and helping ensure comprehensive coverage. The 15 cm large field-of-view transducer is easy to position and maintains even compression while scanning. Since no two women are identical, exams can be customized with programmable scan protocols, adjustable scan depths and compression levels. With the touch of a button, the operator can also shorten scan time once breast tissue acquisition is complete.

For more information: www.gehealthcare.com

 

References

[1] Increase in cancer detection associated with an overall decrease in false positives.

[2] Brem RF, Tabár L, et.al. Assessing Improvement in Detection of Breast Cancer with Three-dimensional Automated Breast US in Women with Dense Breast Tissue: The SomoInsight Study. Radiology. 2015 Mar; 274(3): 663-73.

[3] https://ww5.komen.org/Breastcancer/Highbreastdensityonmammogram.html

 

Related Content

Fujifilm Sonosite Partnering With Artificial Intelligence Incubator to Improve Ultrasound Image Interpretation
News | Ultrasound Imaging | September 23, 2019
Fujifilm SonoSite Inc. and the Allen Institute of Artificial Intelligence (AI2) Incubator, builder of AI-first startups...
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Numerical simulation with a heterogeneous mouse

Numerical simulation with a heterogeneous mouse. (a) The geometry of the mouse with major organs near the source, and (b) the surface fluence computed with TIM-OS. Image courtesy of Rensselaer Polytechnic Institute.

News | Oncology Diagnostics | September 20, 2019
If researchers could observe drug delivery and its effect on cancer cells in real time, they would be able to tailor...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology

The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology. Image courtesy of Siemens Healthineers.

Technology | Angiography | September 17, 2019
The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems...
3D Systems Earns Additional FDA Clearance for D2P Medical 3-D Printing Software

3D Systems’ D2P FDA-cleared software allows clinicians to 3-D-print diagnostic patient-specific anatomic models. Image courtesy of 3D Systems.

Technology | Medical 3-D Printing | September 12, 2019
3D Systems has received additional U.S. Food and Drug Administration (FDA) 510(k) clearance for its D2P software...
Richardson Healthcare Receives CE Mark Approval for ALTA750 Canon/Toshiba CT Replacement Tube
News | Computed Tomography (CT) | September 11, 2019
Richardson Healthcare, a Division of Richardson Electronics Ltd., announced it has received CE Mark approval for the...
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images

A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images. The algorithm, described at the SBI/ACR Breast Imaging Symposium, used deep learning, a form of machine learning, which is a type of artificial intelligence. Image courtesy of Sarah Eskreis-Winkler, M.D.

Feature | Society of Breast Imaging (SBI) | September 06, 2019 | By Greg Freiherr
The use of smart algorithms has the potential to make healthcare more efficient.